[FG] Yaldizli Özgür

Janiaud, Perrine et al. (2024) ‘MultiSCRIPT-Cycle 1- A Pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in Multiple Sclerosis: a study protocol for a randomized clinical trial’, medRxiv [Preprint]. Cold Spring Harbor Laboratory. Available at: https://doi.org/10.1101/2024.03.22.24304720.

Benkert, Pascal et al. (2024) ‘Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B-Cell Depleting Treatment in Multiple Sclerosis’, Annals of Neurology [Preprint]. Available at: https://doi.org/10.1002/ana.27096.

Janiaud, Perrine et al. (2024) ‘MultiSCRIPT-Cycle 1—a pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in multiple sclerosis: a study protocol for a randomized clinical trial’, Trials. 11.09.2024, 25. Available at: https://doi.org/10.1186/s13063-024-08454-6.

Cortese R. et al. (2023) ‘Clinical and MRI measures to identify non-acute MOG-antibody disease in adults’, Brain, 146(6), pp. 2489–2501. Available at: https://doi.org/10.1093/brain/awac480.

Cerdá-Fuertes, Nuria et al. (2023) ‘Evaluation of frequency, severity, and independent risk factors for recurrence of disease activity after fingolimod discontinuation in a large real-world cohort of patients with multiple sclerosis’, Therapeutic Advances in Neurological Disorders, 16. Available at: https://doi.org/10.1177/17562864221150312.

Stanikić, Mina et al. (2023) ‘Self-reports by persons with multiple sclerosis are an adequate surrogate for healthcare provider data on disease-modifying therapy and multiple sclerosis type’, Multiple Sclerosis and Related Disorders, 80. Available at: https://doi.org/10.1016/j.msard.2023.105097.

Etter M et al. (2022) ‘Severe Neuro-COVID is associated with peripheral immune signatures and signs of neurodegeneration: a prospective cross-sectional study’, in SFCNS. (SFCNS).

Yaldizli Ö and Derfuss T (2022) ‘All Bruton’s tyrosine kinase inhibitors have similar efficacy and risks: Commentary.’, 28(10). Available at: https://doi.org/10.1177/13524585221097562.

Lisa Dinsenbacher and Özgür Yaldizli (2022) ‘MS und Kinderwunsch: Was müssen Betroffene beachten?’, FORTE [Preprint], (3).

Müller J et al. (2022) ‘Choroid Plexus Volume in Multiple Sclerosis vs Neuromyelitis Optica Spectrum Disorder: A Retrospective, Cross-sectional Analysis.’, Neurology(R) neuroimmunology & neuroinflammation, 9(3). Available at: https://doi.org/10.1212/nxi.0000000000001147.

Benkert, Pascal et al. (2022) ‘Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study’, The Lancet Neurology, 21(3), pp. 246–257. Available at: https://doi.org/10.1016/s1474-4422(22)00009-6.

Wolleb, Julia et al. (2022) ‘Learn to Ignore: Domain Adaptation for Multi-site MRI Analysis’, in Medical Image Computing and Computer Assisted Intervention – MICCAI 2022. Singapore, September 18–22, 2022 (Medical Image Computing and Computer Assisted Intervention – MICCAI 2022), pp. 725–735. Available at: https://doi.org/10.1007/978-3-031-16449-1_69.

Sophia Reimann et al. (2022) ‘On the association between the choroid plexus volume and disease characteristics in multiple sclerosis’, in SFCNS. (SFCNS).

Oechtering J et al. (2021) ‘Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple Sclerosis.’, Annals of neurology, 90(3), pp. 477–489. Available at: https://doi.org/10.1002/ana.26137.

Allum JHJ et al. (2021) ‘Characteristics of improvements in balance control using vibro-tactile biofeedback of trunk sway for multiple sclerosis patients.’, Journal of the neurological sciences, 425, p. 117432. Available at: https://doi.org/10.1016/j.jns.2021.117432.

Tsagkas C et al. (2021) ‘Syndrome of inappropriate antidiuretic hormone secretion and hypothalamic hypocortisolism in neuromyelitis optica.’, Lancet (London, England), 397(10290), p. 2194. Available at: https://doi.org/10.1016/s0140-6736(21)00986-7.

Lorscheider J et al. (2021) ‘Comparative analysis of dimethyl fumarate and fingolimod in relapsing-remitting multiple sclerosis.’, Journal of neurology, 268(3), pp. 941–949. Available at: https://doi.org/10.1007/s00415-020-10226-6.

von Wyl V et al. (2021) ‘Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate.’, Multiple sclerosis (Houndmills, Basingstoke, England), 27(3), pp. 439–448. Available at: https://doi.org/10.1177/1352458520918489.

Jakimovski D et al. (2020) ‘Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study.’, Multiple sclerosis (Houndmills, Basingstoke, England), 26(13), pp. 1670–1681. Available at: https://doi.org/10.1177/1352458519881428.

Kronlage C et al. (2020) ‘Muscle stiffness, gait instability, and liver cirrhosis in Wilson’s disease.’, Lancet (London, England), 396(10256), p. 990. Available at: https://doi.org/10.1016/s0140-6736(20)31963-2.

von Wyl V et al. (2020) ‘Influence of age at disease onset on future relapses and disability progression in patients with multiple sclerosis on immunomodulatory treatment.’, European journal of neurology, 27(6), pp. 1066–1075. Available at: https://doi.org/10.1111/ene.14191.

Sander L et al. (2020) ‘Improving Accuracy of Brainstem MRI Volumetry: Effects of Age and Sex, and Normalization Strategies.’, Frontiers in neuroscience, 14, p. 609422. Available at: https://doi.org/10.3389/fnins.2020.609422.

Sinnecker T et al. (2020) ‘New and enlarging white matter lesions adjacent to the ventricle system and thalamic atrophy are independently associated with lateral ventricular enlargement in multiple sclerosis.’, Journal of neurology, 267(1), pp. 192–202. Available at: https://doi.org/10.1007/s00415-019-09565-w.

Kaufmann M et al. (2019) ‘A Framework for Estimating the Burden of Chronic Diseases: Design and Application in the Context of Multiple Sclerosis.’, Frontiers in neurology, 10, p. 953. Available at: https://doi.org/10.3389/fneur.2019.00953.

Barro C et al. (2018) ‘Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis.’, Brain : a journal of neurology, 141(8), pp. 2382–2391. Available at: https://doi.org/10.1093/brain/awy154.

Lorscheider J et al. (2018) ‘Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.’, Multiple sclerosis (Houndmills, Basingstoke, England), 24(6), pp. 777–785. Available at: https://doi.org/10.1177/1352458518768433.

Miller DH et al. (2018) ‘Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study.’, Annals of clinical and translational neurology, 5(3), pp. 346–356. Available at: https://doi.org/10.1002/acn3.534.

Findling O et al. (2018) ‘Balance Changes in Patients With Relapsing-Remitting Multiple Sclerosis: A Pilot Study Comparing the Dynamics of the Relapse and Remitting Phases.’, Frontiers in neurology, 9, p. 686. Available at: https://doi.org/10.3389/fneur.2018.00686.

Neuhaus M et al. (2018) ‘Characterization of social cognition impairment in multiple sclerosis.’, European journal of neurology. 24.10.2017, 25(1), pp. 90–96. Available at: https://doi.org/10.1111/ene.13457.

Ruberte E et al. (2018) ‘Central Slab versus Whole Brain to Measure Brain Atrophy in Multiple Sclerosis.’, European neurology, 80(3-4), pp. 207–214. Available at: https://doi.org/10.1159/000495798.

Yaldizli Ö et al. (2018) ‘Response to the commentary of Yates RL and DeLuca GC on the study: HLA-DRB1*1501 associations with magnetic resonance imaging measures of grey matter pathology in multiple sclerosis.’, 19. Available at: https://doi.org/10.1016/j.msard.2016.08.006.

Barro, C. et al. (2017) ‘Serum neurofilament light chain correlates with disease activity and predicts clinical and MRI outcomes in MS’. SAGE PUBLICATIONS LTD, 23.

Lorscheider, J. et al. (2017) ‘Fingolimod vs. dimethyl fumarate in relapsing-remitting multiple sclerosis: propensity score matched comparison in a large observational data set’. SAGE PUBLICATIONS LTD, 23.

Sinnecker, T. et al. (2017) ‘Comparison between central and whole brain atrophy in multiple sclerosis measured by structural image evaluation using normalization of atrophy (SIENA)’. SAGE PUBLICATIONS LTD, 23.

D’Souza M et al. (2017) ‘Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: A proof of concept study.’, Multiple sclerosis (Houndmills, Basingstoke, England), 23(4), pp. 597–603. Available at: https://doi.org/10.1177/1352458516657439.

Kuhle J et al. (2017) ‘Serum neurofilament is associated with progression of brain atrophy and disability in early MS.’, Neurology, 88(9), pp. 826–831. Available at: https://doi.org/10.1212/wnl.0000000000003653.

Pardini, M et al. (2016) ‘The association between retinal nerve fibre layer thickness and N-acetyl aspartate levels in multiple sclerosis brain normal-appearing white matter: a longitudinal study using magnetic resonance spectroscopy and optical coherence tomography’, EUROPEAN JOURNAL OF NEUROLOGY. WOS.SCI, 23, pp. 1769–1774. Available at: https://doi.org/10.1111/ene.13116.

Pardini M et al. (2016) ‘Relationship of grey and white matter abnormalities with distance from the surface of the brain in multiple sclerosis.’, Journal of neurology, neurosurgery, and psychiatry. 06.09.2016, 87(11), pp. 1212–1217. Available at: https://doi.org/10.1136/jnnp-2016-313979.

Barro, C. et al. (2016) ‘High sensitivity serum neurofilament-light chain measurements correlate with disease activity and disability in multiple sclerosis and are reduced after immunomodulatory treatment intervention.’ SAGE PUBLICATIONS LTD, 22.

Lienert, C. et al. (2016) ‘Lower relapse rates with natalizumab as compared with fingolimod as second-line treatment in relapsing-remitting multiple sclerosis’. SAGE PUBLICATIONS LTD, 22.

Ruberte, E. et al. (2016) ‘Lateral Ventricle Volume change is associated with neurological and cognitive disability in multiple sclerosis: a 5-years follow-up study using an automated lateral ventricle segmentation algorithm’. SAGE PUBLICATIONS LTD, 22.

Ruberte, E. et al. (2016) ‘Validation of an automated lateral ventricle delineation algorithm (ALVIN) in multiple sclerosis’. SAGE PUBLICATIONS LTD, 22.

van de Pavert, S. H. et al. (2016) ‘Spatial and temporal characteristics of magnetisation transfer ratio changes in different corticothalamic systems in multiple sclerosis’. SAGE PUBLICATIONS LTD, 22.

van der Logt RP et al. (2016) ‘The effect of vibrotactile biofeedback of trunk sway on balance control in multiple sclerosis.’, Multiple sclerosis and related disorders, 8, pp. 58–63. Available at: https://doi.org/10.1016/j.msard.2016.05.003.

Yaldizli Ö et al. (2016) ‘HLA-DRB*1501 associations with magnetic resonance imaging measures of grey matter pathology in multiple sclerosis.’, Multiple sclerosis and related disorders. 07.03.2016, 7, pp. 47–52. Available at: https://doi.org/10.1016/j.msard.2016.03.003.

Datta, Gourab et al. (2016) ‘Cortical [11C]PBR28 PET Measures of Microglial Inflammation Explain Differences in Cognitive Performance of People with MS’, NEUROLOGY. WOS.ISTP, 86.

Yaldizli Ö et al. (2016) ‘The association between olfactory bulb volume, cognitive dysfunction, physical disability and depression in multiple sclerosis’, European Journal of Neurology, 23(3), pp. 510–519. Available at: https://doi.org/10.1111/ene.12891.

Yaldizli Ö et al. (2016) ‘Characteristics of lesional and extra-lesional cortical grey matter in relapsing-remitting and secondary progressive multiple sclerosis: A magnetisation transfer and diffusion tensor imaging study.’, Multiple sclerosis (Houndmills, Basingstoke, England). 26.05.2015, 22(2), pp. 150–9. Available at: https://doi.org/10.1177/1352458515586085.

Callegari I et al. (2016) ‘Agomelatine Improves Apathy in Frontotemporal Dementia.’, Neuro-degenerative diseases. 27.05.2016, 16(5-6), pp. 352–6. Available at: https://doi.org/10.1159/000445873.

Disanto, G. et al. (2016) ‘The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options’, PLoS One, 11(3), p. e0152347. Available at: https://doi.org/10.1371/journal.pone.0152347.

Kuhle, Jens et al. (2016) ‘Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity’, Multiple Sclerosis Journal, 22(12), pp. 1550–1559. Available at: https://doi.org/10.1177/1352458515623365.

Pardini M et al. (2016) ‘Prevalence and cognitive underpinnings of isolated apathy in young healthy subjects.’, Journal of affective disorders. 08.10.2015, 189, pp. 272–5. Available at: https://doi.org/10.1016/j.jad.2015.09.062.

Pardini M et al. (2015) ‘Motor network efficiency and disability in multiple sclerosis.’, Neurology. 28.08.2015, 85(13), pp. 1115–22. Available at: https://doi.org/10.1212/wnl.0000000000001970.

Liu Z et al. (2015) ‘Magnetization transfer ratio measures in normal-appearing white matter show periventricular gradient abnormalities in multiple sclerosis.’, Brain : a journal of neurology. 29.03.2015, 138(Pt 5), pp. 1239–46. Available at: https://doi.org/10.1093/brain/awv065.

Kuhle, J. et al. (2015) ‘Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study’, Multiple Sclerosis Journal, 21(8), pp. 1013–24. Available at: https://doi.org/10.1177/1352458514568827.

Liu Z et al. (2015) ‘Cervical cord area measurement using volumetric brain magnetic resonance imaging in multiple sclerosis.’, Multiple sclerosis and related disorders. 18.11.2014, 4(1), pp. 52–7. Available at: https://doi.org/10.1016/j.msard.2014.11.004.

Chard,DT et al. (2015) ‘Association of Multiple Sclerosis Normal Appearing White Matter Abnormality with Periventricular Location and Secondary Progression’, p. P6.126.

Pardini,M et al. (2015) ‘The relationship of a multi-parameter MRI measure of motor network efficiency with disability in multiple sclerosis’, p. P6.129.

Yaldizli,O et al. (2015) ‘Diffusion Tensor Imaging Abnormalities in Multiple Sclerosis Cortical Lesions and Normal-Appearing Grey Matter and their Associations with Disability’, p. P6.108.

Flachenecker P et al. (2014) ‘Multiple sclerosis registries in Europe - results of a systematic survey.’, Multiple sclerosis (Houndmills, Basingstoke, England). 28.04.2014, 20(11), pp. 1523–32. Available at: https://doi.org/10.1177/1352458514528760.

Pardini M et al. (2014) ‘Isolated cognitive relapses in multiple sclerosis.’, Journal of neurology, neurosurgery, and psychiatry. 31.03.2014, 85(9), pp. 1035–7. Available at: https://doi.org/10.1136/jnnp-2013-307275.

Papadopoulou A et al. (2014) ‘MRI characteristics of periaqueductal lesions in multiple sclerosis.’, Multiple sclerosis and related disorders, 3(4), pp. 542–51. Available at: https://doi.org/10.1016/j.msard.2014.01.001.

Papadopoulou, A. et al. (2014) ‘Lesion-to-ventricle distance and other risk factors for the persistence of newly formed black holes in relapsing-remitting multiple sclerosis’, Multiple Sclerosis Journal, 20(3), pp. 322–30. Available at: https://doi.org/10.1177/1352458513495583.

Yaldizli, O. et al. (2014) ‘The relationship between total and regional corpus callosum atrophy, cognitive impairment and fatigue in multiple sclerosis patients’, Multiple Sclerosis Journal, 20(3), pp. 356–364. Available at: https://doi.org/10.1177/1352458513496880.

Pardini,M et al. (2014) ‘Network Efficiency As A Final Common Pathway For Cognitive Deficits In Multiple Sclerosis: A Single Network Graph Theory Study.’, p. P6.128.

Corporaal, Sharissa H A et al. (2013) ‘Balance control in multiple sclerosis : correlations of trunk sway during stance and gait tests with disease severity’, Gait & posture, 37(1), pp. 55–60. Available at: https://doi.org/10.1016/j.gaitpost.2012.05.025.

Hafner P, Yaldizli O and Baumann T (2013) ‘Schwindel aus neurologischer Sicht unter spezieller Berücksichtigung von Notfallsituationen.’, Therapeutische Umschau. Revue therapeutique, 70(1), pp. 12–4. Available at: https://doi.org/10.1024/0040-5930/a000356.

Kuhle, J et al. (2013) ‘Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis’, Acta neurologica scandinavica, 128(6), pp. e33–6. Available at: https://doi.org/10.1111/ane.12151.

van Dijk, Jitse P. et al. (2013) ‘Influence of Disease Severity on Fatigue in Patients with Parkinson’s Disease Is Mainly Mediated by Symptoms of Depression’, EUROPEAN NEUROLOGY. WOS.SSCI, 70, pp. 201–209. Available at: https://doi.org/10.1159/000351779.

Yaldizli O. et al. (2013) ‘Neurologist-in-training: Multiple sclerosis’, Schweizer Archiv fur Neurologie und Psychiatrie, 164(1), pp. 37–40. Available at: https://doi.org/10.4414/sanp.2013.00103.

Hafner,Patricia, Yaldizli,Özgür and Baumann,Thomas (2013) ‘Schwindel aus neurologischer Sicht unter spezieller Berücksichtigung von Notfallsituationen’, Ther Umsch, 70(3), pp. 12–4.

Yaldizli,O et al. (2013) ‘Resident corner 2012: Multiple sclerosis’, Schweizer Archiv für Neurologie und Psychiatrie, 164(4), pp. 37–40.

Zwahlen,D et al. (2013) ‘Theory of mind deficits in patients with multiple sclerosis – a separate entity of socio-cognitive impairment?’, p. 990.

Fanchamps, Malou H J et al. (2012) ‘Screening for balance disorders in mildly affected multiple sclerosis patients’, Journal of neurology, 259(7), pp. 1413–9. Available at: https://doi.org/10.1007/s00415-011-6366-5.

Gensicke, H. et al. (2012) ‘Monoclonal Antibodies and Recombinant Immunoglobulins for the Treatment of Multiple Sclerosis’, CNS Drugs, 26(1), pp. 11–37. Available at: https://doi.org/10.2165/11596920-000000000-00000.

Lienert,C et al. (2012) ‘Immunomodulatory treatment of multiple sclerosis in Switzerland – a nationwide follow-up of 8046 patients’, p. 213.

Yaldizli,O (2012) ‘Immunmodulierende Basistherapie nach dem ersten Schub einer möglichen Multiple Sklerose’, pp. 58–62.

Yonekawa,T et al. (2012) ‘Olfactory bulb volume and neuropsychological performance, fatigue severity and depression in multiple sclerosis patients’, p. 378.

Yaldizli Ö et al. (2011) ‘Fatigue and progression of corpus callosum atrophy in multiple sclerosis.’, Journal of neurology. 19.05.2011, 258(12), pp. 2199–205. Available at: https://doi.org/10.1007/s00415-011-6091-0.

Kuhle, Jens et al. (2011) ‘Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS’, Neurology, 77(23), pp. 2010–6. Available at: https://doi.org/10.1212/wnl.0b013e31823b9b27.

Yaldizli O. et al. (2011) ‘Neurologist-in-training’, Schweizer Archiv fur Neurologie und Psychiatrie, 162(4), pp. 171–173. Available at: https://doi.org/10.4414/sanp.2011.02270.

Yaldizli,O et al. (2011) ‘Resident corner 2011: Multiple sclerosis’, Schweizer Archiv für Neurologie und Psychiatrie, 162(3), pp. 171–173.

Gasperini, Claudio, Ruggieri, Serena and Pozzilli, Carlo (2010) ‘Emerging oral treatments in multiple sclerosis - clinical utility of cladribine tablets.’, Therapeutics and clinical risk management. 07.09.2010, 6, pp. 391–9. Available at: https://doi.org/10.2147/tcrm.s6639.

Yaldizli O et al. (2010) ‘Corpus callosum index and long-term disability in multiple sclerosis patients.’, Journal of neurology. 03.03.2010, 257(8), pp. 1256–64. Available at: https://doi.org/10.1007/s00415-010-5503-x.

Papadopoulou, Athina et al. (2010) ‘Dimethyl fumarate for multiple sclerosis’, Expert opinion on investigational drugs, 19(12), pp. 1603–12. Available at: https://doi.org/10.1517/13543784.2010.534778.

Putzki N et al. (2010) ‘Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland.’, European neurology. 16.01.2010, 63(2), pp. 101–6. Available at: https://doi.org/10.1159/000276400.

Putzki N et al. (2010) ‘Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.’, European journal of neurology, 17(1), pp. 31–7. Available at: https://doi.org/10.1111/j.1468-1331.2009.02728.x.

Wurst, Friedrich M. (2010) ‘Risk factors for suicide attempts in patients with alcohol dependence or abuse and a history of depressive symptoms : a subgroup analysis from the WHO/ISBRA study’, Drug and alcohol review, 29(1), pp. 64–74. Available at: https://doi.org/10.1111/j.1465-3362.2009.00089.x.

Menegola,M et al. (2010) ‘Magnetic resonance imaging predictors of the persistence of T1 black holes in multiple sclerosis patients’, p. 316.

Yaldizli,O et al. (2010) ‘Bildgebung bei MS: MRT für Diagnose, Verlaufskontrolle und Therapieplanung’, 8(3), pp. 6–8.

Yaldizli,O et al. (2010) ‘Regional corpus callosum atrophy, cognitive dysfunction and fatigue in multiple sclerosis patients’, p. 809.

Putzki N et al. (2009) ‘Multiple sclerosis associated fatigue during natalizumab treatment.’, Journal of the neurological sciences. 26.06.2009, 285(1-2), pp. 109–13. Available at: https://doi.org/10.1016/j.jns.2009.06.004.

Yaldizli O and Tettenborn B (2009) ‘[After lymph node biopsy. Pain and weakness in the right shoulder].’, MMW Fortschritte der Medizin, 151(39), p. 5.

Obermann M et al. (2009) ‘Substantia nigra hyperechogenicity and CSF dopamine depletion in HIV.’, Journal of neurology. 25.02.2009, 256(6), pp. 948–53. Available at: https://doi.org/10.1007/s00415-009-5052-3.

Yaldizli O, Baumberger P and Putzki N (2009) ‘[Natalizumab and atypical naevi: Comments on the pharmacovigilance note by J.-L. Schmutz et al].’, 136(5). Available at: https://doi.org/10.1016/j.annder.2009.03.018.

Yaldizli O and Putzki N (2009) ‘Natalizumab in the treatment of multiple sclerosis.’, Therapeutic advances in neurological disorders, 2(2), pp. 115–28. Available at: https://doi.org/10.1177/1756285608101861.

Putzki N et al. (2009) ‘Prevalence of migraine, tension-type headache and trigeminal neuralgia in multiple sclerosis.’, European journal of neurology. 09.12.2008, 16(2), pp. 262–7. Available at: https://doi.org/10.1111/j.1468-1331.2008.02406.x.

Yaldizli O et al. (2009) ‘Fatigue is not associated with impaired function of regulatory T cells in untreated patients with multiple sclerosis.’, European neurology, 62(6), pp. 321–6. Available at: https://doi.org/10.1159/000236375.

Putzki,N et al. (2009) ‘Natalizumab reduces clinical and MRI disesase activity in second line treatment of relapsing-remitting multiple sclerosis: results of a multi-center study.’, p. A236.

Putzki,N et al. (2009) ‘Natalizumab disproportionally increases circulating B cells and decreases the frequency of natural T regulatory cells.’, p. 166.